drugset / Trial / NCT03555123

Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX

NCT03555123

Phase 3 Unknown 112 enrolled Yooyoung Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind, Multicenter, parallel, placebo-controlled study

Timeline

Start
2019-01-11
Primary completion
2022-01-30
Completion
2022-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Levosimendan Other / unclassified 2.5 mg/ml Intravenous

Indications